Cargando…
OR10-04 Interpretation of Insulin-like Growth Factor-1 (IGF-1) Levels Following Administration of Somatrogon (a Long-acting Human Growth Hormone - hGH-CTP)
IGF-1 is often used as a biomarker to evaluate the efficacy and safety of hGH replacement therapy. Typically, the mean IGF-1 SDS level during the dosing interval, rather than the peak value, guides clinical decision-making: sustained mean values > +2 may require hGH dose modifications. With long-...
Autores principales: | Fisher, Dennis M, Pastrak, Aleksandra, Choe, John, Wajnrajch, Michael Paul, Cara, José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209021/ http://dx.doi.org/10.1210/jendso/bvaa046.504 |
Ejemplares similares
-
OR21-04 Long-term Efficacy And Safety Of Once-weekly Somatrogon In Pediatric Subjects With Growth Hormone Deficiency: Results From Up To 8 Years Of Somatrogon Treatment
por: Zadik, Zvi, et al.
Publicado: (2023) -
OR10-06 Somatrogon Growth Hormone in the Treatment of Pediatric Growth Hormone Deficiency: Results of the Pivotal Pediatric Phase 3 Clinical Trial
por: Deal, Cheri L, et al.
Publicado: (2020) -
Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers
por: Lewis, Andrew L., et al.
Publicado: (2015) -
Testosterone, cortisol, hGH, and IGF‐1 levels in an Italian female elite volleyball team
por: Roli, Laura, et al.
Publicado: (2018) -
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
por: Deal, Cheri L, et al.
Publicado: (2022)